CSIR And Laxai Life Sciences Begin Clinical Trials Of Niclosamide Drug For Treating COVID-19
CSIR in collaboration with Laxai Life Sciences Pvt. Ltd., has initiated Phase-II clinical trial with anti-helminitic drug Niclosamide for treatment of Covid-19. The trial is a multi-centric, phase-II, randomized, open…
Share